Dr. Christien Kluwe, a radiation oncologist at Mays Cancer Center at UT Health San Antonio, is calling for a new approach to managing prostate cancer in light of advancements in technology and longer life expectancy among patients. In his research, Kluwe is exploring radiation techniques like stereotactic body radiation therapy as part of his efforts to balance disease control and quality of life in the treatment of prostate cancer.
Kluwe has raised questions about the necessity of androgen deprivation therapy, such as testosterone blockers, for all prostate cancer patients. He believes that it is essential to identify those patients who would benefit significantly from a decrease in testosterone levels and tailor the treatment accordingly. The oncologist emphasizes the importance of avoiding unnecessary treatments for patients who may not derive significant benefits from such therapies.
With the use of tiny pellets the size of grains of rice, radiation can be delivered directly to the cancer cells over a span of five days, sparing healthy tissues from damage. This innovative approach to treatment has revolutionized the care of prostate cancer patients, offering a more efficient and effective method of managing the disease. The collaboration between TPR and The University of Texas Health Science Center at San Antonio aims to highlight scientific advancements in medicine that have the potential to improve patient outcomes.
Prostate cancer is the most common cancer diagnosed in men, with a five-year survival rate of 97%. Despite this high survival rate, Kluwe believes that there is still much work to be done in terms of improving patient outcomes through new approaches to management. With his research into radiation techniques like stereotactic body radiation therapy, he hopes to make a significant impact on the lives of men with prostate cancer.
In conclusion, Dr. Christien Kluwe’s work highlights the need for new approaches to managing prostate cancer that prioritize both disease control and quality